ClinicalTrials.gg
RecruitingNCT07400393MCSPUpdated Nov 12, 2026

Healey ALS MyMatch Common Screening Protocol

An observational study in ALS, ALS (Amyotrophic Lateral Sclerosis) and ALS - Amyotrophic Lateral Sclerosis, sponsored by Massachusetts General Hospital. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Massachusetts General Hospital · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 12, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Amyotrophic Lateral Sclerosis by Massachusetts General Hospital — 3 open to participants now, 3 under way, none of them phase 3. Amyotrophic Lateral Sclerosis · Massachusetts General Hospital.

Planned enrollment
2nd of 10
500 · median 130
Started
2026
with 1 other
Observational
10 of 20
2 open now
Registered
20th of 20
by date

Among the 20 studies in Amyotrophic Lateral Sclerosis by Massachusetts General Hospital, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2026, is one of 10 observational ones, and was the 20th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

3 of the 20 studies in Amyotrophic Lateral Sclerosis by Massachusetts General Hospital are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Amyotrophic Lateral Sclerosis by Massachusetts General Hospital, or all of them as a file.
02

Study summary

The Healey ALS MyMatch Common Screening Protocol (MCSP) is an observational study. The main goal of the study is to help connect adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.

People who complete an MCSP Screening Visit will undergo:

  • clinical assessments
  • laboratory testing
  • biomarker analyses

The above will be used to determine preliminary eligibility for enrolling ALS MyMatch trials. In addition to helping connect people to a Healey ALS MyMatch interventional clinical trial, the information will also be used to characterize clinical, genetic, and biofluid biomarker profiles. These profiles will help to match the right people to the right trials and evaluate the frequency of ALS-associated gene variants. Blood samples and DNA will also be stored for future ALS and biomarker research.

Read the detailed description

The MyMatch Common Screening Protocol (MCSP) is an observational study that is part of the Healey ALS MyMatch program. Healey ALS MyMatch is an early phase (Phase 1b or 2a), Amyotrophic Lateral Sclerosis (ALS) clinical trial program. ALS MyMatch is designed to help match adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.

The first step in participating in Healey ALS MyMatch is to complete a screening visit for the MCSP. MCSP screening visit activities can be completed over a period of 45-days and some screening visit activities can be completed remotely. MCSP screening visit activities include:

  • obtaining informed consent
  • reviewing medical history
  • collecting blood samples
  • completing a 12-lead ECG
  • completing questionnaires

To be eligible to participate in the MCSP, the following key criteria will need to be met: ALS diagnosis, SVC breathing score of equal to or greater than 65%, and ALS genetic testing.

The information collected at the MCSP screening visit helps researchers determine whether a participant might qualify for one or more treatment studies that are currently enrolling in the ALS MyMatch program. If a participant appears eligible for more than one study, then the participant may choose to consult with their doctor and decide which study would be a better fit for them.

03

Conditions studied

  • ALS
  • ALS (Amyotrophic Lateral Sclerosis)
  • ALS - Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • Amyotrophic Lateral Sclerosis
  • MyMatch
  • ALS MyMatch
  • MyMatch Program
  • MCSP
  • MyMatch Common Screening Protocol
  • Early Phase
  • Biomarker
  • Phase I
  • Phase II
  • Healey
  • NCRI
  • ALS Trials
  • MGB
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target populations for MCSP and ALS MyMatch trials will initially focus on subgroups of individuals with ALS, including those with early-stage disease. Some ALS MyMatch trials will further target those with specific biomarkers or genetic markers for inclusion in a specific trial.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide written .
  2. Adults > 18 years of age.
  3. Diagnosis of symptomatic ALS that meets either the revised El Escorial Criteria.(clinically possible, probable, probable lab-supported, or definite) or the Gold Coast Criteria.
  4. Available or pending clinically obtained CLIA ALS genetic panel report.
  5. Time since onset of weakness due to ALS ≤ 24 months at the time of MCSP screening.
  6. Slow VC ≥ 65% of predicted capacity value for gender, height and age at screening.
  7. Clinically unremarkable Complete Blood Counts as per SI's discretion, including but not limited to ≥ 9 g/dL.
  8. Ability and willingness to complete all study procedures per SI's assessment.
  9. Negative pregnancy test at screening for women of (WOCB), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months).

Exclusion criteria

Exclusion Criteria:

  1. unstable medical or surgical condition that would pose a risk to the participant's trial procedural participation or interfere with data collection, per SI's assessment.
  2. Presence of cognitive or mental health disorders impairing ability to provide for the study per SI assessment.
  3. Active cancer or history of cancer, unless it was successfully treated for durable remission or cure more than 3 years ago. (Note that basal cell carcinoma, squamous cell carcinoma in situ, cervical carcinoma in situ, prostatic carcinoma in situ, or other that have been curatively excised at any time previously and with no evidence of disease recurrence for at least 3 years are not exclusionary.)
  4. Prior solid organ transplantation.
  5. Use of treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the MCSP Screening Visit. (Please refer to the Manual of Procedures (MOP) for current list of experimental therapies)
  6. Screening 12-lead showing corrected for rate (QTcF) > 470 msec for women and > 450 msec for men, absence of second degree or higher AV block or other clinically significant cardiac arrythmias.
  7. Clinically significant abnormalities in the Comprehensive Metabolic Panel per SI's assessment, including but not limited to:

    1. Serum or aspartate aminotransferase > 3 times the , or serum > 1.5 × upper limit of normal
    2. Estimated (eGFR) of \< 30 mL/min/1.73m2
  8. Other clinically significant electrolyte and metabolic abnormalities
  9. If female, breastfeeding, pregnant, or of and unwilling to use effective for duration of the trial and after discontinuing treatment as outlined in the ALS MyMatch trial protocol.
  10. Clinically significant unstable medical conditions (other than ALS) that would pose a risk to the participant, per SI's assessment (e.g., cardiovascular instability, systemic infection,), or clinically significant laboratory abnormality or ECG changes.
  11. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).
  12. Participants who require Permanent assisted ventilation (PAV). PAV defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
45 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Preliminary eligibility to be matched to a MyMatch Trial

    To determine preliminary eligibility of early ALS (\< 24 months from weakness onset) participants for actively enrolling ALS MyMatch trial(s)

    Time frame: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.

Secondary outcomes

  1. Repository for future research

    To build an ALS biofluid, genetic and data repository for future clinical and translational research.

    Time frame: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

  2. Prevalence of gene mutations

    To characterize the prevalence of participants with causative or risk modifier gene mutations in the MCSP

    Time frame: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

  3. Collect and bank samples

    To collect and bank blood samples for future biofluid biomarker analyses

    Time frame: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.

07

Study locations

1 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2029, 30 months after the start.

Of 129 non-industry observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's planned 30 months is below that.

Counting every sponsor, half of 138 studies reached it within 64 months; a quarter within 29 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 10, 2026
StartActual
Aug 31, 2026
Primary completionEst.
Mar 16, 2029
CompletionEst.
Mar 16, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • Nova Southeastern University · Davie, United States
  • Northwestern University · Chicago, United States
  • Massachusetts General Hospital · Boston, United States
  • University of Minnesota · Minneapolis, United States
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    4 sites added — first site in United States
    Show 4 added (4 United States)
    • Nova Southeastern University · Davie, United States
    • Northwestern University · Chicago, United States
    • Massachusetts General Hospital · Boston, United States
    • University of Minnesota · Minneapolis, United States
    + 3 other changes: verification date, date precision and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07400393
Responsible party
Suma Babu (Associate Professor of Neurology at Harvard Medical School and Co-Director of the Neurological Clinical Research Institute (NCRI), Massachusetts General Hospital) — Principal investigator
First posted
Feb 10, 2026
Start date
Aug 31, 2026
Primary completion
Mar 16, 2029 (estimated)
Completion
Mar 16, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Healey ALS MyMatch Clinical Operations Team
Contact
mghalsmymatch@mgb.org
857-282-9210

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion